Eisai, Biogen to Launch Global PIII for Alzheimer’s Drug by March-End

Eisai said on August 9 that it plans to begin a global PIII study in Japan, the US, and Europe with Biogen to gauge the efficacy of their BACE inhibitor E2609 in early Alzheimer’s disease (AD) now that the partners...read more